secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001628280-26-021578
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio FY2025 net loss $61.4M; SENTI-202 gets RMAT, Phase 1 data encouraging
-------------------------------------------------------------------------------

- Net loss $61.4M for FY2025 ($2.73/share); Q4 loss $14.5M ($0.53/share).
- Cash and equivalents $16.4M as of December 31, 2025.
- SENTI-202 received RMAT designation for relapsed/refractory AML; updated Phase 1 data show encouraging responses and safety.
- R&D expenses $37.6M full year; G&A expenses $26.2M full year, down in Q4 YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000162828026021578/0001628280-26-021578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000162828026021578/snti-20260327.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-021578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer